LinkedIn Profile

Access Yaupon Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:yaupontherapeutics 1651483 Jun 4th, 2019 12:00AM Yaupon Therapeutics, Inc 48 9.00 Open Biotechnology Jun 4th, 2019 03:26PM Jun 4th, 2019 03:26PM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Open Open 259 Radnor Chester Road Radnor Pa US 19087 Health Care Equipment & Services
private:yaupontherapeutics 1651483 Mar 26th, 2018 12:00AM Yaupon Therapeutics, Inc 40 9.00 Open Biotechnology Mar 26th, 2018 04:52PM Mar 26th, 2018 04:52PM Open Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 17th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 16th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 15th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 14th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 13th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 12th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 11th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services
private:yaupontherapeutics 1651483 Feb 10th, 2018 12:00AM Yaupon Therapeutics, Inc 39 9.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status. Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.